NeurogesX Reports Second Quarter 20...(Other assets ...)

Date:8/7/2009

Other assets -- 4 -- -- Total assets $63,276 $25,590 ======= ======= Liabilities and Stockholders' Equity Current liabilities: Accounts payable $490 $370 Accrued compensation 873 1,039 Accrued research and development 445 1,067 Other accrued expenses 915 540 Deferred revenue 4,304 -- Notes payable - current portion 1,273 2,833 ----- ----- Total current liabilities 8,300 5,849 Non-current liabilities: Deferred revenue 44,483 -- Notes payable - non-current portion -- 191 Deferred rent 354 276 --- --- Total non-current liabilities 44,837 467 Commitments and contingencies Stockholders' equity: Common stock 18 18 Additional paid-in capital 210,296 209,370 Deferred stock-based compensation -- (2) Accumulated other comprehensive income 2 32 Deficit accumulated during the development stage (200,177) (190,144) --------- --------- Total stockholders' equity
'/>"/>

SOURCE NeurogesX, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
2. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
3. NeurogesX Added to Russell 3000 Index
4. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
5. NeurogesX to Present at Needham Life Sciences Conference
6. NeurogesX Receives European Commission Approval for Qutenza(TM)
7. NeurogesX Reports First Quarter 2009 Results
8. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
9. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
10. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
11. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union